Important !!!The emphasis - I mean, the only project mentionned - in the PR
"a canine oncology product that is based on the Company's Mycobacterial Cell Wall-DNA Complex (MCC) technology"
this can be a winner if it is properly marketted by, for ex., Bayer, their Australian partner.